Survey Results
| Site | Clinical dosimetry? | Billing for SPECT? Dosimetry? | Dosimetry of all clinical patients or subset? | Optional: RPT dosimetry for clinical trials |
|---|---|---|---|---|
| 1 | No | Yes (SPECT) | Subset (unspecified) | Yes (internal and external trials) |
| 2 | Yes | Yes (SPECT) | Subset (single/compromised kidney function, significant bone mets/lung mets, retreatment) | No response |
| 3 | Yes | No | Subset (those who agree to multiple imaging) | No response |
| 4 | Yes | Yes (SPECT) | Subset (reduced kidney function, other risk factors) | No response |
| 5 | Yes (131I, no 177Lu) | Yes (SPECT and dosimetry) | Subset (131I, suspected lung mets) | No response |
| 6 | No | No (not performed) | No | No |
| 7 | No | No (not performed) | No | No |
| 8 | No | No (not performed) | No | Yes (internal trials) |
| 9 | No | No (not performed) | No | Yes (internal trials) |
| 10 | No | No (not performed) | No | No |
| 11 | Yes | Yes (SPECT and dosimetry) | Subset (attending physician driven) | No |
| 12 | Yes (131I, 90Y, 131I-iobenguane, no 177Lu) | Yes (SPECT) | Subset (unspecified) | Yes (internal trials) |
| 13 | No | No (not performed) | No | Yes (internal trials) |
| 14 | Yes | No | Subset (131I, suspected lung mets, 177Lu pending) | No |
| 15 | Yes | Yes (unspecified) | Subset (all 90Y, 177Lu renal insufficiency, previously treated, borderline marrow function, previously irradiated organs) | Yes (internal and external trials) |
| 16 | No | No (not performed) | No | No |
| 17 | Yes | Yes (SPECT) | Subset (177Lu-DOTATATE) | Yes (internal trials) |
| 18 | Yes | Yes (SPECT and dosimetry) | Subset (131I, compromised renal function; 177Lu, compromised renal function or low blood counts for marrow toxicity) | Yes (internal trials) |
| 19 | Yes | Yes (SPECT) | Subset (unspecified) | Yes (internal trials) |
| 20 | No | Yes (SPECT) | Subset (177Lu, all except those who cannot return) | Yes (internal trials) |
Mets = metastases.